AndreasKKleinMD

Hematology • Boston, MA

Hematologic Oncology

Wellforce

Join to view full profile

Dr. Klein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Klein's full profile

Already have an account?

Office
750 Washington St
Boston, MA 02111
Phone+1 617-636-5000

Fax+1 617-636-6204

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1998 - 2001
Tufts Medical CenterResidency, Internal Medicine, 1995 - 1998
Yale School of MedicineClass of 1995

Certifications & Licensure

MA State Medical License 2001 - 2025
NH State Medical License 2024 - 2024
ME State Medical License 2020 - 2021
NC State Medical License 1998 - 2001
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014, 2016-2017, 2019-2022
Super Doctor SuperDoctors.com

Clinical Trials

Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy Start of enrollment: 2004 Apr 01
Terminated
Phase 1
A Phase II Study of Umbilical Cord Blood Transplantation Start of enrollment: 2005 Jul 01
Terminated
Phase 2
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Start of enrollment: 2004 Sep 21
Completed
Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma Start of enrollment: 2008 Apr 01
Terminated
Phase 2
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Start of enrollment: 2013 Jan 01
Completed
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation Start of enrollment: 2013 Jul 01
Terminated
Phase 1
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.
Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo Gordon, Jane Winter
Blood Advances. 2024-04-09
4 citations
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
James N Gerson, Elizabeth Handorf, Diego Villa, Alina S Gerrie, Parv Chapani
Blood Advances. 2023-12-26
8 citations
Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma.
Jenica N Upshaw, Jason Nelson, Angie Mae Rodday, Anita J Kumar, Andreas K Klein
JAMA Cardiology. 2023-05-01

Journal Articles

Clinicopathologic Characteristics of Secondary Squamous Cell Carcinoma of Head and Neck in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation for Hematolo...
Kenneth B Miller, Kellie A Sprague, Chakra P Chaulagain, Esha Kaul, Andreas K Klein, Janet Cowan, Nature

Abstracts/Posters

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas
Andreas Klein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
Andreas Klein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Supervised Machine Learning Algorithms Using Patient Related Factors to Predict in-Hospital Mortality Following Acute Myeloid Leukemia Therapy
Andreas Klein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

Center for Health Literacy Research + PracticeAugust 23rd, 2024
Development and Clinical Application of CD19xCD3 and CD20xCD3 Bispecific AntibodiesJanuary 17th, 2022
Old Idea, New Desperation: Can Plasma from Recovered Patients Help Those Now Battling COVID-19?May 22nd, 2020
Join now to see all